RT Journal Article
SR Electronic
T1 Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.07.22283104
DO 10.1101/2022.12.07.22283104
A1 Kampaite, Agniete
A1 Gustafsson, Rebecka
A1 York, Elizabeth N.
A1 Foley, Peter
A1 MacDougall, Niall J. J.
A1 Bastin, Mark E.
A1 Chandran, Siddharthan
A1 Waldman, Adam D.
A1 Meijboom, Rozanna
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2022.12.07.22283104.abstract
AB Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system, characterised by neuroinflammation and neurodegeneration. Fatigue and depression are common, debilitating, and intertwined symptoms in people with relapsing-remitting MS (pwRRMS). An increased understanding of brain changes and mechanisms underlying fatigue and depression in RRMS could lead to more effective interventions and enhancement of quality of life. To elucidate the relationship between depression and fatigue and brain connectivity in pwRRMS we conducted a systematic review.Searched databases were PubMed, Web-of-Science and Scopus. Inclusion criteria were: studied participants with RRMS and differentiated between MS subtypes; published between 2001-01-01 and 2023-01-18; used fatigue and depression assessments validated for MS; included brain structural, functional magnetic resonance imaging (fMRI) or diffusion MRI (dMRI). Sixty studies met the criteria: 18 dMRI (15 fatigue, 5 depression) and 22 fMRI (20 fatigue, 5 depression) studies.The literature was heterogeneous; half of studies reported no correlation between brain connectivity measures and fatigue or depression. Positive findings showed that abnormal cortico-limbic structural and functional connectivity was associated with depression. Fatigue was linked to connectivity measures in cortico-thalamic-basal-ganglial networks. Additionally, both depression and fatigue were related to altered cingulum structural connectivity, and functional connectivity involving thalamus, cerebellum, frontal lobe, ventral tegmental area, striatum, default mode and attention networks, and supramarginal, precentral, and postcentral gyri.Qualitative analysis suggests neuropathological effects, possibly due to axonal and/or myelin damage, in the cortico-thalamic-basal-ganglial and cortico-limbic network may underlie fatigue and depression in pwRRMS, respectively, but the overall results were inconclusive. This highlights the need for studies including advanced MRI to detect more subtle brain changes in association with depression and fatigue as functional and microstructural studies more consistently show correlations. Further studies using optimised imaging protocols and validated depression and fatigue measures are required to clarify the substrate underlying these symptoms in pwRRMS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by MS Society Edinburgh Centre for MS Research [grant reference 133] (AK, RM), Chief Scientist Office SPRINT MND/MS program (ENY), the Anne Rowling Regenerative Neurology Clinic (ENY), and the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimers Society and Alzheimers Research UK (SC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper is a systematic review. We summarised data from other published papers. The list of papers used is in the manuscript.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.